A systematic review of persistence and compliance with bisphosphonates for osteoporosis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-02-17

AUTHORS

J. A. Cramer, D. T. Gold, S. L. Silverman, E. M. Lewiecki

ABSTRACT

Fourteen reports utilizing data from de-identified administrative databases were reviewed. Studies contained at least one measure of patient persistence or compliance with bisphosphonates or bisphosphonates and other anti-osteoporosis medications. These studies confirm that women with osteoporosis have suboptimal persistence and compliance rates with bisphosphonate therapy.IntroductionThis review summarizes patient persistence and compliance with bisphosphonates for the treatment of osteoporosis.MethodsWe conducted a MEDLINE search for the period from January 1998 to May 2006, using a detailed list of terms related to persistence and compliance with anti-osteoporosis medications. Studies were included if they contained at least one measure of persistence or compliance derived from de-identified administrative databases containing patient demographics and prescription information.ResultsWe reviewed 14 reports, which described 14 databases. The percentage of patients persisting with therapy for 1 year ranged from 17.9% to 78.0%. Compliance, assessed as mean medication possession ratio (MPR), ranged from 0.59 to 0.81. When comparing compliance with weekly and daily bisphosphonates, the mean MPR was consistently higher for weekly versus daily therapy (0.58 to 0.76 versus 0.46 to 0.64 for patients receiving weekly and daily bisphosphonate therapy respectively). Persistence was also improved in patients receiving weekly bisphosphonates, assessed by both length of persistence (194 to 269 days [weekly] and 134 to 208 days [daily]) and percentage of persistent patients at the end of the follow-up period (35.7% to 69.7% [weekly] and 26.1% to 55.7% [daily]).ConclusionAlthough patients using weekly bisphosphonate medication follow their prescribed dosing regimens better than those using daily therapy, overall compliance and persistence rates were suboptimal. More... »

PAGES

1023-1031

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-006-0322-8

DOI

http://dx.doi.org/10.1007/s00198-006-0322-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1012288373

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17308956


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diphosphonates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hormone Replacement Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Compliance", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, 06516-2770, West Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, 06516-2770, West Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cramer", 
        "givenName": "J. A.", 
        "id": "sg:person.01132106034.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132106034.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Medical Center, Durham, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gold", 
        "givenName": "D. T.", 
        "id": "sg:person.0657120700.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657120700.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cedars-Sinai Medical Center, UCLA, Beverly Hills, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Cedars-Sinai Medical Center, UCLA, Beverly Hills, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Silverman", 
        "givenName": "S. L.", 
        "id": "sg:person.0750301114.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750301114.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA", 
          "id": "http://www.grid.ac/institutes/grid.419992.e", 
          "name": [
            "New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lewiecki", 
        "givenName": "E. M.", 
        "id": "sg:person.0756034765.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756034765.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00198-003-1431-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032558418", 
          "https://doi.org/10.1007/s00198-003-1431-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0073-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020337646", 
          "https://doi.org/10.1007/s00198-006-0073-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-004-1652-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023624379", 
          "https://doi.org/10.1007/s00198-004-1652-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002230020037", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038583086", 
          "https://doi.org/10.1007/s002230020037"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-003-1502-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013179474", 
          "https://doi.org/10.1007/s00198-003-1502-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-005-1957-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035467750", 
          "https://doi.org/10.1007/s00198-005-1957-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0085-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019542455", 
          "https://doi.org/10.1007/s00198-006-0085-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-02-17", 
    "datePublishedReg": "2007-02-17", 
    "description": "Fourteen reports utilizing data from de-identified administrative databases were reviewed. Studies contained at least one measure of patient persistence or compliance with bisphosphonates or bisphosphonates and other anti-osteoporosis medications. These studies confirm that women with osteoporosis have suboptimal persistence and compliance rates with bisphosphonate therapy.IntroductionThis review summarizes patient persistence and compliance with bisphosphonates for the treatment of osteoporosis.MethodsWe conducted a MEDLINE search for the period from January 1998 to May 2006, using a detailed list of terms related to persistence and compliance with anti-osteoporosis medications. Studies were included if they contained at least one measure of persistence or compliance derived from de-identified administrative databases containing patient demographics and prescription information.ResultsWe reviewed 14 reports, which described 14 databases. The percentage of patients persisting with therapy for 1\u00a0year ranged from 17.9% to 78.0%. Compliance, assessed as mean medication possession ratio (MPR), ranged from 0.59 to 0.81. When comparing compliance with weekly and daily bisphosphonates, the mean MPR was consistently higher for weekly versus daily therapy (0.58 to 0.76 versus 0.46 to 0.64 for patients receiving weekly and daily bisphosphonate therapy respectively). Persistence was also improved in patients receiving weekly bisphosphonates, assessed by both length of persistence (194 to 269\u00a0days [weekly] and 134 to 208\u00a0days [daily]) and percentage of persistent patients at the end of the follow-up period (35.7% to 69.7% [weekly] and 26.1% to 55.7% [daily]).ConclusionAlthough patients using weekly bisphosphonate medication follow their prescribed dosing regimens better than those using daily therapy, overall compliance and persistence rates were suboptimal.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00198-006-0322-8", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "mean medication possession ratio", 
      "anti-osteoporosis medications", 
      "daily therapy", 
      "patient persistence", 
      "administrative databases", 
      "percentage of patients", 
      "medication possession ratio", 
      "treatment of osteoporosis", 
      "suboptimal persistence", 
      "bisphosphonate therapy", 
      "daily bisphosphonates", 
      "weekly bisphosphonates", 
      "ConclusionAlthough patients", 
      "bisphosphonate medication", 
      "patient demographics", 
      "possession ratio", 
      "persistent patients", 
      "length of persistence", 
      "MEDLINE search", 
      "prescription information", 
      "bisphosphonates", 
      "overall compliance", 
      "compliance rate", 
      "patients", 
      "systematic review", 
      "therapy", 
      "medications", 
      "osteoporosis", 
      "persistence rates", 
      "compliance", 
      "regimens", 
      "review", 
      "MethodsWe", 
      "percentage", 
      "database", 
      "persistence", 
      "women", 
      "demographics", 
      "ResultsWe", 
      "study", 
      "period", 
      "treatment", 
      "measures", 
      "report", 
      "rate", 
      "years", 
      "search", 
      "data", 
      "list", 
      "measures of persistence", 
      "ratio", 
      "end", 
      "length", 
      "detailed list", 
      "information", 
      "terms"
    ], 
    "name": "A systematic review of persistence and compliance with bisphosphonates for osteoporosis", 
    "pagination": "1023-1031", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1012288373"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-006-0322-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17308956"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-006-0322-8", 
      "https://app.dimensions.ai/details/publication/pub.1012288373"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_448.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00198-006-0322-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-006-0322-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-006-0322-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-006-0322-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-006-0322-8'


 

This table displays all metadata directly associated to this object as RDF triples.

219 TRIPLES      21 PREDICATES      99 URIs      84 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-006-0322-8 schema:about N43c78eab4533428fb00c99ca231022eb
2 N854fd8f759d246caa8ad2ac7954a21ea
3 N9015324480c94e6fba46ea20916df48c
4 N9e8851b63d424816867f5c3bad59aca4
5 Nb0c02e7b2e5d4c309758e30e8f3ea2e8
6 Nb7ca00a7609647d0bc6c8f41ddf23cf0
7 Nc213e9c14ad74b6c9dcafec3302ac040
8 Nc61f8f06dfdd4df69aad35bba0f27ede
9 Ndc4e15ee9bd24318b2c3e434ba57f02f
10 Nde60024cfaee412c975ee1985687a2d1
11 Ne5b9b126daed4ff6bf33a72aab0de318
12 anzsrc-for:11
13 anzsrc-for:1103
14 schema:author N3549324e0c9945ca838a763dfbaab552
15 schema:citation sg:pub.10.1007/s00198-003-1431-2
16 sg:pub.10.1007/s00198-003-1502-4
17 sg:pub.10.1007/s00198-004-1652-z
18 sg:pub.10.1007/s00198-005-1957-6
19 sg:pub.10.1007/s00198-006-0073-6
20 sg:pub.10.1007/s00198-006-0085-2
21 sg:pub.10.1007/s002230020037
22 schema:datePublished 2007-02-17
23 schema:datePublishedReg 2007-02-17
24 schema:description Fourteen reports utilizing data from de-identified administrative databases were reviewed. Studies contained at least one measure of patient persistence or compliance with bisphosphonates or bisphosphonates and other anti-osteoporosis medications. These studies confirm that women with osteoporosis have suboptimal persistence and compliance rates with bisphosphonate therapy.IntroductionThis review summarizes patient persistence and compliance with bisphosphonates for the treatment of osteoporosis.MethodsWe conducted a MEDLINE search for the period from January 1998 to May 2006, using a detailed list of terms related to persistence and compliance with anti-osteoporosis medications. Studies were included if they contained at least one measure of persistence or compliance derived from de-identified administrative databases containing patient demographics and prescription information.ResultsWe reviewed 14 reports, which described 14 databases. The percentage of patients persisting with therapy for 1 year ranged from 17.9% to 78.0%. Compliance, assessed as mean medication possession ratio (MPR), ranged from 0.59 to 0.81. When comparing compliance with weekly and daily bisphosphonates, the mean MPR was consistently higher for weekly versus daily therapy (0.58 to 0.76 versus 0.46 to 0.64 for patients receiving weekly and daily bisphosphonate therapy respectively). Persistence was also improved in patients receiving weekly bisphosphonates, assessed by both length of persistence (194 to 269 days [weekly] and 134 to 208 days [daily]) and percentage of persistent patients at the end of the follow-up period (35.7% to 69.7% [weekly] and 26.1% to 55.7% [daily]).ConclusionAlthough patients using weekly bisphosphonate medication follow their prescribed dosing regimens better than those using daily therapy, overall compliance and persistence rates were suboptimal.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf N47a332f09c3d446c9ad55ab4e95e6fd1
28 Ndf48893d35fa48cd80f0335b581aeb0b
29 sg:journal.1100834
30 schema:keywords ConclusionAlthough patients
31 MEDLINE search
32 MethodsWe
33 ResultsWe
34 administrative databases
35 anti-osteoporosis medications
36 bisphosphonate medication
37 bisphosphonate therapy
38 bisphosphonates
39 compliance
40 compliance rate
41 daily bisphosphonates
42 daily therapy
43 data
44 database
45 demographics
46 detailed list
47 end
48 information
49 length
50 length of persistence
51 list
52 mean medication possession ratio
53 measures
54 measures of persistence
55 medication possession ratio
56 medications
57 osteoporosis
58 overall compliance
59 patient demographics
60 patient persistence
61 patients
62 percentage
63 percentage of patients
64 period
65 persistence
66 persistence rates
67 persistent patients
68 possession ratio
69 prescription information
70 rate
71 ratio
72 regimens
73 report
74 review
75 search
76 study
77 suboptimal persistence
78 systematic review
79 terms
80 therapy
81 treatment
82 treatment of osteoporosis
83 weekly bisphosphonates
84 women
85 years
86 schema:name A systematic review of persistence and compliance with bisphosphonates for osteoporosis
87 schema:pagination 1023-1031
88 schema:productId N07b3a26abed444dea18c61b78f4ad136
89 N0920a6593c054fdbbfee153a9c8cee34
90 N8ac2581ba7f540c9b9e40ace483a4253
91 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012288373
92 https://doi.org/10.1007/s00198-006-0322-8
93 schema:sdDatePublished 2022-12-01T06:26
94 schema:sdLicense https://scigraph.springernature.com/explorer/license/
95 schema:sdPublisher N4a9bec4fa6bd49b89987df24724bb8bd
96 schema:url https://doi.org/10.1007/s00198-006-0322-8
97 sgo:license sg:explorer/license/
98 sgo:sdDataset articles
99 rdf:type schema:ScholarlyArticle
100 N07b3a26abed444dea18c61b78f4ad136 schema:name doi
101 schema:value 10.1007/s00198-006-0322-8
102 rdf:type schema:PropertyValue
103 N0920a6593c054fdbbfee153a9c8cee34 schema:name dimensions_id
104 schema:value pub.1012288373
105 rdf:type schema:PropertyValue
106 N3549324e0c9945ca838a763dfbaab552 rdf:first sg:person.01132106034.52
107 rdf:rest N9f671c0707ee4a4fbf95dbe1abc5ef94
108 N43c78eab4533428fb00c99ca231022eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Osteoporosis
110 rdf:type schema:DefinedTerm
111 N454d6d8aabee4249a8ea770528d88851 rdf:first sg:person.0750301114.52
112 rdf:rest Ne1c4062b53ed42fdbbedec05220c6145
113 N47a332f09c3d446c9ad55ab4e95e6fd1 schema:issueNumber 8
114 rdf:type schema:PublicationIssue
115 N4a9bec4fa6bd49b89987df24724bb8bd schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 N854fd8f759d246caa8ad2ac7954a21ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Middle Aged
119 rdf:type schema:DefinedTerm
120 N8ac2581ba7f540c9b9e40ace483a4253 schema:name pubmed_id
121 schema:value 17308956
122 rdf:type schema:PropertyValue
123 N9015324480c94e6fba46ea20916df48c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Drug Administration Schedule
125 rdf:type schema:DefinedTerm
126 N9e8851b63d424816867f5c3bad59aca4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Female
128 rdf:type schema:DefinedTerm
129 N9f671c0707ee4a4fbf95dbe1abc5ef94 rdf:first sg:person.0657120700.21
130 rdf:rest N454d6d8aabee4249a8ea770528d88851
131 Nb0c02e7b2e5d4c309758e30e8f3ea2e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Hormone Replacement Therapy
133 rdf:type schema:DefinedTerm
134 Nb7ca00a7609647d0bc6c8f41ddf23cf0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Patient Compliance
136 rdf:type schema:DefinedTerm
137 Nc213e9c14ad74b6c9dcafec3302ac040 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Diphosphonates
139 rdf:type schema:DefinedTerm
140 Nc61f8f06dfdd4df69aad35bba0f27ede schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Osteoporosis, Postmenopausal
142 rdf:type schema:DefinedTerm
143 Ndc4e15ee9bd24318b2c3e434ba57f02f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Bone Density Conservation Agents
145 rdf:type schema:DefinedTerm
146 Nde60024cfaee412c975ee1985687a2d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Humans
148 rdf:type schema:DefinedTerm
149 Ndf48893d35fa48cd80f0335b581aeb0b schema:volumeNumber 18
150 rdf:type schema:PublicationVolume
151 Ne1c4062b53ed42fdbbedec05220c6145 rdf:first sg:person.0756034765.55
152 rdf:rest rdf:nil
153 Ne5b9b126daed4ff6bf33a72aab0de318 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Adult
155 rdf:type schema:DefinedTerm
156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
157 schema:name Medical and Health Sciences
158 rdf:type schema:DefinedTerm
159 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
160 schema:name Clinical Sciences
161 rdf:type schema:DefinedTerm
162 sg:journal.1100834 schema:issn 0937-941X
163 1433-2965
164 schema:name Osteoporosis International
165 schema:publisher Springer Nature
166 rdf:type schema:Periodical
167 sg:person.01132106034.52 schema:affiliation grid-institutes:grid.47100.32
168 schema:familyName Cramer
169 schema:givenName J. A.
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132106034.52
171 rdf:type schema:Person
172 sg:person.0657120700.21 schema:affiliation grid-institutes:grid.189509.c
173 schema:familyName Gold
174 schema:givenName D. T.
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657120700.21
176 rdf:type schema:Person
177 sg:person.0750301114.52 schema:affiliation grid-institutes:grid.19006.3e
178 schema:familyName Silverman
179 schema:givenName S. L.
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750301114.52
181 rdf:type schema:Person
182 sg:person.0756034765.55 schema:affiliation grid-institutes:grid.419992.e
183 schema:familyName Lewiecki
184 schema:givenName E. M.
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756034765.55
186 rdf:type schema:Person
187 sg:pub.10.1007/s00198-003-1431-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032558418
188 https://doi.org/10.1007/s00198-003-1431-2
189 rdf:type schema:CreativeWork
190 sg:pub.10.1007/s00198-003-1502-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013179474
191 https://doi.org/10.1007/s00198-003-1502-4
192 rdf:type schema:CreativeWork
193 sg:pub.10.1007/s00198-004-1652-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1023624379
194 https://doi.org/10.1007/s00198-004-1652-z
195 rdf:type schema:CreativeWork
196 sg:pub.10.1007/s00198-005-1957-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035467750
197 https://doi.org/10.1007/s00198-005-1957-6
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s00198-006-0073-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020337646
200 https://doi.org/10.1007/s00198-006-0073-6
201 rdf:type schema:CreativeWork
202 sg:pub.10.1007/s00198-006-0085-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019542455
203 https://doi.org/10.1007/s00198-006-0085-2
204 rdf:type schema:CreativeWork
205 sg:pub.10.1007/s002230020037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038583086
206 https://doi.org/10.1007/s002230020037
207 rdf:type schema:CreativeWork
208 grid-institutes:grid.189509.c schema:alternateName Duke University Medical Center, Durham, NC, USA
209 schema:name Duke University Medical Center, Durham, NC, USA
210 rdf:type schema:Organization
211 grid-institutes:grid.19006.3e schema:alternateName Cedars-Sinai Medical Center, UCLA, Beverly Hills, CA, USA
212 schema:name Cedars-Sinai Medical Center, UCLA, Beverly Hills, CA, USA
213 rdf:type schema:Organization
214 grid-institutes:grid.419992.e schema:alternateName New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
215 schema:name New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
216 rdf:type schema:Organization
217 grid-institutes:grid.47100.32 schema:alternateName Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, 06516-2770, West Haven, CT, USA
218 schema:name Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, 06516-2770, West Haven, CT, USA
219 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...